<DOC>
	<DOCNO>NCT02688361</DOCNO>
	<brief_summary>This open-label , randomize , single-center , 2-period , 2-sequence , single-dose crossover design study adult male female healthy participant . Eligible participant receive either treatment A ( reference ) : Fluimucil® Acetylcysteine 2 % oral solution , 200 mg N- acetylcysteine ( NAC ) 10 mL dose , treatment B ( test ) : Acetylcysteine 2 % oral solution , 200 mg NAC 10 mL dose . Blood sample collect pre-dose 48 hour period . After completion second study period ( i.e . last pharmacokinetic ( PK ) sample Day 3 Period 2 ) participant discharge clinic .</brief_summary>
	<brief_title>A Bioequivalence Study Acetylcysteine 2 % Oral Solution Versus Reference Fluimucil 2 % Oral Solution</brief_title>
	<detailed_description />
	<mesh_term>Respiratory Tract Infections</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Acetylcysteine</mesh_term>
	<mesh_term>N-monoacetylcystine</mesh_term>
	<criteria>Participants must understand provide write informed consent assessment perform , understand study procedure , willing complete require assessment . Male female participant ethnic origin 18 45 year age . Body Mass Index ( BMI ) 18.5 30 kg/m2 , inclusive . Minimal body weight 50 kg , inclusive . Normal vital sign follow : Oral body temperature 35.0 37.5 ºC inclusive ; Sitting systolic blood pressure 90 140 mmHg inclusive ; Sitting diastolic blood pressure 55 90 mmHg inclusive ; Sitting pulse rate 50 100 bpm inclusive . In general , good physical health , judge Investigator determine medical/surgical history , physical examination , electrocardiogram ( ECG , 12lead ) clinical laboratory ( clinical chemistry hematology ) finding . Use investigational drug within 3 month 10 halflives enrollment , whichever longer . History known hypersensitivity study drug , excipients drug similar chemical pharmacological class . Diagnosis long QT syndrome QTc ( Fridericia prefer , Bazett acceptable ) ≥ 450 msec male ≥ 470 msec female screen . History malignancy neoplastic disease organ system ( except localize basal cell skin carcinoma ) , treat untreated , within past 5 year prior screen , regardless whether evidence local recurrence metastasis . Pregnant , Women childbearing potential breastfeeding woman . Any surgical medical condition may significantly alter absorption , distribution , metabolism excretion drug substance History ( within 5 year prior study start ) clinically significant gastritis , pyloric channel stenosis , peptic ulcer duodenal ulceration , gastroesophageal reflux , gastrointestinal bleeding , rectal bleeding clinically significant GI abnormality . History ( within 5 year prior study start ) orthostatic hypotension , cardiovascular disease , stroke , transient ischemic attack , faint blackout . Clinically relevant chronic acute infectious illness febrile infection within 2 week prior start study . Newly occur ( within 2 week screen visit ) cutaneous mucosal alteration . Participants histamine intolerance . Positive result virology test Human Immunodeficiency VirusAb , Hepatitis C Antibody ( HCVAb ) , Surface Antigen Hepatitis B Virus ( HBsAg ) , Hepatitis B Core Antibody ( HBcAb ) . Any evidence clinically significant cardiovascular , pulmonary , renal , hepatic , gastrointestinal , hematological , endocrinological , metabolic , autoimmune , neurological , psychiatric disease screen . Participant use medication ( include overthecounter medication ) within 2 week first schedule study drug administration within &lt; 10 time elimination halflife respective drug ( whichever longer ) , anticipated require concomitant medication period time throughout study . Participant report consumption drug metabolize enzyme ( e.g . CYP3A4 cytochrome P450 enzyme ) induce inhibit aliment , beverage food supplement within two week prior first schedule study drug administration , anticipated consume product twoweek period time throughout study . Any history drug hypersensitivity , asthma , urticaria , significant allergic diathesis , illicit drug abuse . Participant show evidence current alcohol abuse smoking . `` Vulnerable '' individual . Participation previous clinical study without another investigational product ~470 ml blood drawn , blood donation within last 3 month prior screen previous enrollment current study . Any condition identify protocol , opinion Investigator , would confound evaluation interpretation study data may put participant risk .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>